MILWAUKEE, Sept. 11, 2013 (GLOBE NEWSWIRE) -- We are investigating possible securities fraud claims against OvaScience Inc. resulting from inaccurate statements OvaScience made regarding its financial statements and prospects.
Click here to learn more about the investigation: http://www.ademilaw.com/case/ovascience or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Our investigation focuses on the extent to which OvaScience issued false and misleading statements regarding its financial statement, past and future business performance and prospects. Specifically, OvaScience failed to disclose that its determination that its infertility therapy AUGMENT is a cellular and tissue-based product, and as such, could be marketed commercially without FDA oversight or review as a drug was based on inaccurate and incomplete analysis and clinical testing. Based on the foregoing, OvaScience lacked a reasonable basis for their positive statements about the Company's infertility therapy AUGMENT during the Class Period. On September 11, 2013, shares of OvaScience fell more than $4.30 or approximately 30% after OvaScience announced that the FDA was questioning AUGMENT's status as a lower-risk form of a human cellular and tissue-based product. The FDA instructed OvaScience to file an investigational new drug application for AUGMENT, which would require rounds of clinical testing and could keep the treatment from reaching the U.S. market for years.
If you wish to obtain additional information or have information about OvaScience, please contact Guri Ademi either at firstname.lastname@example.org or toll-free: 866-264-3995, http://www.ademilaw.com/case/ovascience.
We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Ademi & O'Reilly, LLP Guri Ademi 3620 East Layton Ave. Cudahy, WI 53110 Toll Free: (866) 264-3995 Fax: (414) 482-8001 www.ademilaw.comSource:Ademi & O'Reilly, LLP